<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3960">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04617535</url>
  </required_header>
  <id_info>
    <org_study_id>R10933-10987-COV</org_study_id>
    <nct_id>NCT04617535</nct_id>
  </id_info>
  <brief_title>Compassionate Use of REGN-COV2 for the Treatment of COVID-19</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      Provide Compassionate Use access to REGN-COV2 for adult patients with recently diagnosed&#xD;
      mild-to-moderate coronavirus disease (COVID-19) who are at high risk for poor outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compassionate Use requests are only being considered in response to Individual Patient&#xD;
      Investigational New Drug (IND) applications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Covid19</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN10933+REGN10987 combination therapy</intervention_name>
    <description>Administered intravenously (IV) single dose</description>
  </intervention>
  <overall_contact>
    <last_name>Requests for compassionate use must be initiated by a treating physician. Physicians should contact</last_name>
    <phone>844-734-6643</phone>
    <email>CompassionateUse_Requests@regeneron.com</email>
  </overall_contact>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

